Notice on Convening the 2025 Annual General Meeting
Filed with SSE · · 5 pages · Chinese
Mayinglong Pharmaceutical Group Co., Ltd. on 6ix
Earlier from Mayinglong Pharmaceutical
- Announcement on Obtaining Drug Registration Certificate by Subsidiary
- Announcement on Termination of the Transfer of Equity of Subsidiary Holding Company by the Holding Subsidiary
- 2025 Annual Report
- Announcement on Transfer of Equity of Subsidiary Holding Company by the Holding Subsidiary
- Announcement on Extending Usage Period for Credit Guarantee Limits for Some Subsidiaries
Later from Mayinglong Pharmaceutical
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Obtaining Drug Registration Certificate
- Announcement on Attending the 2026 Collective Reception Day for Investors of Listed Companies in Hubei Jurisdiction
- Announcement on the Inclusion of the Company's Pharmaceutical Products in the "National Essential Medicines List"
Follow Mayinglong Pharmaceutical into a list and get an email when it puts out news.
Follow Mayinglong Pharmaceutical